Literature DB >> 10718546

In situ hybridization and immunohistochemistry study of thyroid peroxidase expression in thyroid tumors.

C De Micco1, F Kopp, V Vassko, M Grino.   

Abstract

Malignant thyroid tumors reportedly exhibit an anomaly in thyroid peroxidase (TPO) resulting in a lower affinity for monoclonal antibody 47 (mAb 47) in immunohistochemistry studies. The purpose of the present study was to compare TPO immunostaining in normal, benign, and malignant thyroid tissue with expression of mRNA sequences in four exons of the molecule including the epitope of mAb 47. TPO immunostaining was performed using mAb 47 and a polyclonal antibody (pAb). Messenger RNA expression was investigated by in situ hybridization using probes specific for mRNA sequences in exons 2, 12 (epitope of mAb), 15, and 17. As expected, pAb immunostaining was significantly positive on all benign tumors and 50% of carcinomas. With mAb 47, little or no immunostaining was observed in 16 of 17 carcinomas while significantly positive immunostaining was found in normal tissue and benign tumors. In situ hybridization showed a decrease and heterogeneity in the expression of all mRNA sequences in carcinomas as compared to normal tissue and benign tumors. Unlike the other three probes, the probe specific for exon 12 hybridized strongly with benign tumors but poorly with most carcinomas. Poor hybridization was usually correlated with defective mAb 47 immunostaining. These results confirm that TPO is expressed in thyroid carcinomas but in smaller amounts than in normal tissue and benign tumors. In malignant tumors, qualitative changes in TPO may also impede mAb 47 immunostaining. In situ hybridization showed a concomitant decrease in the corresponding TPO mRNA sequence. These changes could be due to abnormalities in the maturation of TPO mRNA leading to a different splicing variant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718546     DOI: 10.1089/thy.2000.10.109

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  5 in total

1.  Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors.

Authors:  Svetlana Savin; Dubravka Cvejic; Tijana Isic; Ivana Petrovic; Ivan Paunovic; Svetislav Tatic; Marija Havelka
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

2.  Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer: a novel molecular marker?

Authors:  Sandra J Roddiger; Heiner Renneberg; Thomas Martin; Ulf W Tunn; Nikolaos Zamboglou; Ralf Kurek
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-12       Impact factor: 4.553

3.  Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto's Thyroiditis.

Authors:  Xiao-Xiong Gan; Ya-Yi Li; Si-Jin Li; Shi-Sen Mo; Jian-Hua Feng; Fei Shen; Wen-Song Cai; Ye-Qian Lai; Bo Xu
Journal:  Front Oncol       Date:  2021-08-04       Impact factor: 6.244

4.  Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.

Authors:  C de Micco; V Savchenko; R Giorgi; F Sebag; J-F Henry
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

5.  The value of thyroperoxidase as a prognostic factor for differentiated thyroid cancer -- a long-term follow-up study.

Authors:  Yurena Caballero; Eudaldo M López-Tomassetti; Julián Favre; José R Santana; Juan J Cabrera; Juan R Hernández
Journal:  Thyroid Res       Date:  2015-08-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.